Ownership and insider activity for Eli Lilly and Company (LLY): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500).
Price
| Price | $1,143.12 |
| Market Cap | $1.1T |
| Exchange | NYSE |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-21 | Sulzberger Gabrielle | A-Award | 4 | $5K |
| 2026-09-21 | LUCIANO JUAN R | A-Award | 13 | $16K |
| 2026-09-21 | Fyrwald J Erik | A-Award | 8 | $10K |
| 2026-09-21 | Alvarez Ralph | A-Award | 10 | $12K |
| 2025-09-22 | Seymour Melissa | G-Gift | 17 | |
| 2026-09-09 | Seymour Melissa | G-Gift | 12 | |
| 2025-11-07 | Brown Adrienne S | |||
| 2026-09-02 | Hernandez Edgardo | G-Gift | 13 | |
| 2026-09-02 | Dozier Eric | G-Gift | 216 | |
| 2026-08-17 | Sulzberger Gabrielle | A-Award | 4 | $5K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.58B | $6.54B | $7.32B | $2.34B | $3.66B | $3.82B | $2.07B | $2.82B | $3.27B | $7.16B |
| Short-term Investments | $1.46B | $1.50B | $88.2M | $101.0M | $24.2M | $90.1M | $144.8M | $109.1M | $154.8M | $105.0M |
| Receivables | $4.77B | $5.26B | $5.78B | $5.54B | $6.93B | $8.13B | $8.56B | $11.34B | $13.28B | $20.16B |
| Inventory | $3.56B | $4.46B | $3.10B | $3.19B | $3.98B | $3.89B | $4.31B | $5.77B | $7.59B | $13.74B |
| Total Current Assets | $15.10B | $19.20B | $20.55B | $13.71B | $17.46B | $18.45B | $18.03B | $25.73B | $32.74B | $55.63B |
| Property, Plant & Equipment | $8.25B | $8.83B | $8.00B | $8.40B | $8.68B | $8.99B | $10.14B | $12.91B | $17.10B | $24.68B |
| Goodwill | $3.97B | $4.37B | $1.37B | $3.68B | $3.77B | $3.89B | $4.07B | $4.94B | $5.77B | $5.90B |
| Intangible Assets | $4.36B | $4.03B | $1.07B | $6.62B | $7.45B | $7.69B | $7.21B | $6.91B | $6.17B | $6.52B |
| Total Assets | $38.81B | $44.98B | $43.91B | $39.29B | $46.63B | $48.81B | $49.49B | $64.01B | $78.71B | $112.48B |
| Accounts Payable | $1.35B | $1.41B | $1.21B | $1.41B | $1.61B | $1.67B | $1.93B | $2.60B | $3.23B | $5.38B |
| Short-term Debt | $1.94B | $3.71B | $1.10B | $1.50B | $8.7M | $1.54B | $1.50B | $6.90B | $5.12B | $1.64B |
| Total Current Liabilities | $10.99B | $14.54B | $11.89B | $11.78B | $12.48B | $15.05B | $17.14B | $27.29B | $28.38B | $35.23B |
| Long-term Debt | $8.37B | $9.93B | $9.20B | $13.82B | $16.59B | $15.35B | $14.74B | $18.32B | $28.53B | $40.87B |
| Total Liabilities | $24.73B | $33.31B | $33.00B | $36.59B | $40.81B | $39.65B | $38.71B | $53.14B | $64.44B | $85.94B |
| Retained Earnings | $16.05B | $13.89B | $11.40B | $4.92B | $7.83B | $8.96B | $10.04B | $10.31B | $13.54B | $24.47B |
| Total Equity | $14.01B | $11.59B | $9.83B | $2.61B | $5.64B | $8.98B | $10.65B | $10.77B | $14.19B | $26.54B |
| Total Debt | $10.31B | $13.65B | $10.30B | $15.80B | $16.60B | $16.88B | $16.24B | $25.23B | $33.64B | $42.50B |
| Net Debt | $4.27B | $5.61B | $2.89B | $13.37B | $12.91B | $12.98B | $14.03B | $22.30B | $30.22B | $35.23B |
| Working Capital | $4.11B | $4.67B | $8.66B | $1.93B | $4.98B | $3.40B | $896.3M | -$1.57B | $4.36B | $20.40B |
Financial Health
| Debt / Equity | 1.62 |
| Current Ratio | 1.35 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 8.71 |
Profitability
| Return on Equity | 92.58% |
| Return on Invested Capital | 31.00% |
| Return on Assets | 18.77% |
| Gross Margin | 83.40% |
| Operating Margin | 49.72% |
| Net Margin | 33.53% |
Related companies: ABBV · AMGN · AZN · GILD · JNJ · MRK · NVO
Explore sector: Healthcare · Drug Manufacturers - General
More sections of LLY: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks